ÌìÃÀ´«Ã½

Elias Jabbour

Elias Jabbour

favorite_border

University of Texas MD Anderson Cancer Center

Expertise: Leukemia

Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX


No Research/Citations

Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.
27-Nov-2024 05:05:51 PM EST

ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
31-May-2024 08:00:44 AM EDT

ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
08-Dec-2023 01:15:34 PM EST

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.08235